Quotient Clinical (“the company”), a provider of outsourced, early stage drug development services to the pharmaceutical industry, has been acquired from the Quotient Bioresearch Group by Bridgepoint ...

NOTTINGHAM, England, Sept. 2, 2025 /PRNewswire/ -- Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a ...

NOTTINGHAM, England, Dec. 4, 2025 /PRNewswire/ -- Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Intrepid Labs, the AI leader in pharmaceutical ...

Molecular Disease Screening Microarray Feasibility Study Completed Initial Serological Disease Screening FDA 510(k) Submission Accepted Commencement of EU Expanded Immunohematology Field Trial ...

Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO).

Quotient Bioscience Group, the UK company making its mark in early-stage drug development, has delivered on its recent promise to carry on pursuing a vigorous expansion strategy by acquiring ...

The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, Mass., and CAMBRIDGE, United Kingdom, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company ...

The new website highlights the company’s key focus areas of Chemistry and Metabolism, Clinical and Bioanalytical Sciences and provides visitors with a wealth of information on Quotient’s innovative ...

Employing over 200 people, Quotient Clinical has developed a platform which offers an integrated approach to formulation development, “real-time” drug product manufacturing and clinical testing. Using ...

NOTTINGHAM, England--(BUSINESS WIRE)--Quotient Sciences (“Quotient”), the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing ...